Medical Crossfire®: How Can We Optimize Multidisciplinary Management of Patients With Advanced Endometrial Cancer?
A 1.5-hour Webcast!
This activity is supported by educational grants from
Eisai Inc and Merck Sharp & Dohme Corp.
Eisai Inc and Merck Sharp & Dohme Corp.
Faculty Panel
Ursula A. Matulonis, MD
Director and Chief, Division of Gynecologic Oncology
Susan F. Smith Center for Women’s Cancers
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Lisa Arvine, NP
Nurse Practitioner
Department of Gynecologic Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts
Susana Campos, MD, MPH
Physician
Department of Medical Oncology
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Don S. Dizon, MD, FACP, FASCO
Professor of Medicine
Brown University
Director of Women’s Cancers
Lifespan Cancer Institute
Director of Medical Oncology
Rhode Island Hospital
Providence, Rhode Island
Judith A. Smith, BS, PharmD, BCOP, CPHQ, FCCP, FHOP, FISOPP
Professor & Director of Women’s Health Integrative Medicine
Research Program
Division of Gynecologic Oncology
Department of Obstetrics, Gynecology & Reproductive Sciences
UTHealth McGovern Medical School
Oncology Clinical Pharmacy Specialist
UTHealth – Memorial Hermann Cancer Center – TMC
Houston, Texas
Program Description
This activity, developed in PER®’s established Medical Crossfire® legacy format, is designed to highlight current and emerging data for immune-targeted approaches, including combination therapies, in the treatment of endometrial cancer. Ongoing clinical trials with checkpoint inhibitors and targeted therapies as well as implications for clinical practice and practical application will be reviewed to highlight the future of endometrial cancer therapies. A multidisciplinary team will discuss expert guidance, with a focus on application of core concepts and the use of current and emerging treatment strategies in the care of patients with endometrial cancer.
Target Audience: This educational program is directed toward gynecologic oncologists, medical oncologists, oncology nurses, and health-system pharmacists who treat or manage women with endometrial cancer. Other allied healthcare professionals involved in the treatment and management of endometrial cancer are also invited to participate.
Type of Activity: Application
Release date: November 23, 2020
Expiration date: November 23, 2021
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the impact of advances in diagnosis, prognosis, and treatment of endometrial cancer
- Distinguish the rationale for use of available and emerging treatments for endometrial cancer
- Interpret clinical trial data regarding the safety and efficacy of novel treatment strategies used in endometrial cancer
- Apply strategies the multidisciplinary team can incorporate into the care of patients with endometrial cancer
Pharmacy Times Continuing Education™ is accredited by the Accreditation Councilfor Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-20-377-H01-P. The activity is available for CE credit through November 23, 2021.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC and Pharmacy Times Continuing Education™. Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
For physicians and nurses requesting credit, please visit: https://www.gotoper.com/online-cme-activities/medical-crossfire/mxf-ec2020
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Ursula A. Matulonis, MD, has the following relevant financial relationships with commercial interests to disclose:
Consultant: Merck
Susana Campos, MD, MPH, has the following relevant financial relationships with commercial interests to disclose:
Consultant: Eisai, AstraZeneca
Don S. Dizon, MD, FACP, FASCO, has the following relevant financial relationships with commercial interests to disclose:
Grant Research Support: Bristol Myers Squibb
Consultant: AstraZeneca, Clovis Oncology, Regeneron
Lisa Arvine, NP, and Judith A. Smith, BS, PharmD, BCOP, CPHQ, FCCP, FHOP, FISOPP, have no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™
Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Meg Taylor, PharmD, CPP; Ann Marciano; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.
Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
The staff of Physicians’ Education Resource®, LLC has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
The views expressed in this activity are those of the individual faculty members and do not constitute the views of Pharmacy Times Continuing Education™, Physicians’ Education Resource®, LLC or any of the companies that provided commercial support.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
